<DOC>
	<DOCNO>NCT01090128</DOCNO>
	<brief_summary>The purpose clinical trial test whether treatment patient breast cancer combination Abraxane ( nab-paclitaxel ) , Adriamycin ( doxorubicin ) , Cyclophosphamide prior surgery safe result good tumor response . Up 24 patient may enrol study Mitchell Cancer Institute . All patient enrol study receive treatment combination Abraxane , Adriamycin , Cyclophosphamide .</brief_summary>
	<brief_title>Study Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel , Doxorubicin Cyclophosphamide ( NAC ) Patients With Stages II-III Breast Cancer</brief_title>
	<detailed_description>This single center , open phase I dose escalation study expansion cohort . The dose escalation part study close high tolerable dose nab-paclitaxel ( Abraxane ) assess 100 mg/m2 combination doxorubicin ( Adriamycin ) cyclophosphamide patient stag II-III breast cancer neoadjuvant setting . The initial phase I study objective primarily assess safety drug combination , secondarily obtain preliminary data clinical efficacy combination . 25 patient enrol . The expansion cohort enroll 15 additional patient . The purpose expansion cohort assess pathological complete response .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Histologically cytologically proven adenocarcinoma breast stage IIIII , accord AJCC Staging Manual , 7th Edition , 2009 2 . The following receptor status : Expansion : Triple negative ( ER &lt; 1 % , PR &lt; 1 % , Her2/neu negative Phase 1 ( close ) : Negative Her2/neu status 3 . ECOG performance status 0 1 4 . Negative pregnancy test 5 . Normal cardiac function ( ejection fraction &gt; low limit normal ) determine MUGA echocardiogram 6 . ANC great equal 1,500/mm3 ; platelet great equal 100,000/mm3 ; hemoglobin great equal 9 gm/dL 7 . Serum bilirubin level less equal 1.5 mg/dL 8 . Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) less equal 2.5 X upper limit normal , alkaline phosphatase less equal 2.5 X upper limit normal . 9 . Serum creatinine level less equal 1.5 mg/dL 10 . Women childbearing potential advise avoid become pregnant receive treatment nabpaclitaxel 28 day last dose . Men advise father child receive treatment azacitidine nabpaclitaxel . Appropriate method birth control woman include oral implanted contraceptive , intrauterine device ( IUD ) , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner also base judgment investigator . 11 . Female , great equal 19 year age race . 1 . Concurrent therapy nonprotocol anticancer therapy 2 . For Phase I patient : Current therapy hormone replacement therapy , hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators 3 . Presence neuropathy &gt; grade 2 ( NCICTC version 3.0 ) baseline 4 . History malignancy require active treatment 5 . Clinically significant cardiovascular disease ( e.g. , hypertension [ BP &gt; 150/100 ] , myocardial infarction stroke within 6 month , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication 6 . Currently active infection . 7 . History HIV infection chronic hepatitis B C. 8 . The presence medical psychiatric disorder , opinion treat physician , would contraindicate use drug protocol place subject undue risk treatment complication 9 . Pregnancy breast feed 10 . A history severe hypersensitivity reaction nabpaclitaxel . 11 . Any reason , opinion investigator , patient participate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>